Patients with psychotic disorders often suffer from intercurrent major depressive episodes (MDE). Case reports suggested successful antidepressive treatment with duloxetine, a selective dual reuptake inhibitor of serotonin and norepinephrine. We initiated this open prospective clinical trial to evaluate efficacy, safety and tolerability of this approach. Patients with a psychotic lifetime diagnosis suffering from mildly severe MDE were treated with duloxetine over a period of 6 weeks. We evaluated effects on mood, monitored the psychotic psychopathology and assessed side effects, basal clinical and pharmacological parameters. Twenty patients were included and experienced a significant improvement of their MDE during the observation period (Calgary Depression Scale for Schizophrenia and Hamilton Depression Scale). Psychotic positive symptoms remained stably absent, while negative syndrome and global psychopathology considerably improved (Positive and Negative Syndrome Scale). In general, the treatment was well tolerated, serum prolactin levels stayed unchanged, but pharmacokinetic interactions with a number of antipsychotic agents were observed. This open prospective evaluation showed antidepressive efficacy of duloxetine in patients with co-morbid psychotic disorders. With regard to the psychotic disorder, the treatment appears to be safe and well tolerable. Further investigations should involve a randomized control group.
Addington, D., Addington, J., Atkinson, M. ( 1996) A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res19: 205-212.
2.
Addington, D., Addington, J., Maticka-Tyndale, E., Joyce, J. ( 1992) Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res6: 201-208.
3.
An der Heiden W., Könnecke, R., Maurer, K., Ropeter, D., Häfner, H. ( 2005) Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci255: 174-184.
4.
Andreasen, NC ( 1989) The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry7(Suppl.): 49-58.
5.
Bech, P., Kajdasz, DK, Porsdal, V. ( 2006) Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology188: 273-280.
6.
Collins, AA, Remington, G., Coulter, K., Birkett, K. ( 1996) Depression in schizophrenia: a comparison of three measures . Schizophr Res20: 205-209.
7.
Conley, RR, Ascher-Svanum, H., Zhu, B., Faries, DE, Kinon, BJ ( 2007) The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res90: 186-197.
8.
Detke, MJ, Lu, Y., Goldstein, DJ, Hayes, JR, Demitrack, MA ( 2002) Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry63: 308-315.
9.
Deuschle, M., Mase, E., Zink, M. ( 2006) Dyskinesia during treatment with duloxetine. Pharmacopsychiatry39: 236-238.
10.
Dollfus, S., Olivier, V., Chabot, B., Déal, C., Perrin, E. ( 2005) Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res78: 157-159.
11.
Goldstein, DJ, Lu, Y., Detke, MJ, Wiltse, C., Mallinckrodt, C., Demitrack, MA ( 2004) Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol24: 389-399.
12.
Hamilton, M. ( 1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56-62.
13.
Jockers-Scherubl, MC, Bauer, A., Godemann, F., Reischies, FM, Selig, F., Schlattmann, P. ( 2005) Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol20: 27- 31.
14.
Jost, W., Marsalek, P. ( 2004) Duloxetine: mechanism of action at the lower urinary tract and Onuf’s nucleus. Clin Auton Res14: 220- 227.
15.
Kay, SR, Fiszbein, A., Opler, LA ( 1987) The positive and negative syndrome scale (PANSS) for schizophrenia . Schizophr Bull13: 261- 276.
16.
Kim, SW, Kim, SJ, Yoon, BH, Kim, JM, Shin, IS, Hwang, MY, et al. (2006) Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res144: 57-63.
17.
Kohler, CG, Lallart, EA ( 2002) Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep4: 273-278.
18.
Koran, LM, Aboujaoude, EN, Gamel, NN ( 2007) Duloxetine treatment of dysthymia and double depression: an open-label trial. J Clin Psychiatry68: 761-765.
19.
Kuo, F., Gillespie, TA, Kulanthaivel, P., Lantz, RJ, Ma, TW, Nelson, DL, et al. (2004) Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett14: 3481-3486.
20.
Lantz, RJ, Gillespie, TA, Rash, TJ, Kuo, F., Skinner, M., Kuan, HY, et al. (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos31: 1142-1150.
21.
Maggini, C., Raballo, A. ( 2006) Exploring depression in schizophrenia. Eur Psychiatry21: 227-232.
22.
Mallinckrodt, CH, Raskin, J., Wohlreich, MM, Watkin, JG, Detke, MJ ( 2004) The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry4: 26.
23.
Mazeh, D., Melamed, Y., Elizur, A. ( 1999) Venlafaxine in the treatment of resistant postpsychotic depressive symptoms of schizophrenia. J Clin Psychopharmacol19: 284-285.
24.
Mazeh, D., Shahal, B., Saraf, R., Melamed, Y. ( 2004) Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacol24: 653-655.
Millard, RJ, Moore, K, Rencken, R, Yalcin, I, Bump, RC ; Duloxetine UI Study Group (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int93: 311-318.
27.
Nutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, PL, et al. (2007) The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol21: 461-471.
28.
Palmer, BA, Pankratz, VS, Bostwick, JM ( 2005) The lifetime risk of suicide in schizophrenia. Arch Gen Psychiatry62: 247-253.
29.
Perahia, DG, Gilaberte, I., Wang, F., Wiltse, CG, Huckins, SA, Clemens, JW, et al. (2006) Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry188: 346-353.
30.
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., et al. (2007) Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology192: 441-448.
31.
Poyurovsky, M., Isaacs, I., Fuchs, C., Schneidman, M., Faragian, S., Weizman, R., et al. (2003) Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry160: 297- 302.
32.
Preskorn, SH ( 2004) Duloxetine. J Psychiatr Pract10: 375-385.
33.
Raedler, TJ, Jahn, H., Arlt, J., Kiefer, F., Schick, M., Naber, D., et al. (2004) Adjunctive use of reboxetine in schizophrenia . Eur Psychiatry19: 366-369.
34.
Repo-Tiihonen, E., Eloranta, A., Hallikainen, T., Tiihonen, J. ( 2005) Effects of Venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology51: 173-176.
35.
Rummel, C., Kissling, W., Leucht, S. ( 2006) Antidepressants for the negative symptoms of schizophrenia . Cochrane Database Syst Rev3: CD005581.
36.
Silver, H. ( 2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother5: 2053-2058.
37.
Simpson, GM, Angus, JW ( 1970) A rating scale for extrapyramidal side effects. Acta psychiatr scand212(Suppl.): 11-19.
38.
Siris, SG ( 1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull17: 75-98.
39.
Siris, SG, Bermanzohn, PC, Mason, SE, Shuwall, MA ( 1994) Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry51: 109-115.
40.
Skinner, MH, Kuan, HY, Pan, A., Sathirakul, K., Knadler, MP, Gonzales, CR, et al. (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther73: 170-177.
41.
Spina, E., Avenoso, A., Scordo, MG, Ancione, M., Madia, A., Levita, A. ( 2001) No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit23: 675-678.
42.
Takano, A., Suzuki, K., Kosaka, J., Ota, M., Nozaki, S., Ikoma, Y., et al. (2006) A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology185: 395-399.
43.
Van de Kar, LD, Rittenhouse, PA, Li, Q., Levy, AD ( 1996) Serotonergic regulation of renin and prolactin secretion . Behav Brain Res73: 203-208.
44.
Viktrup, L., Pangallo, PA, Detke, MJ, Zinner, NR ( 2007) Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence. Prim Care Companion J Clin Psychiatry6: 65-73.
45.
Vis, PM, van Baardewijk, M., Einarson, TR ( 2005) Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother39: 1798-1807.
46.
Wetzel, H., Anghelescu, I., Szegedi, A., Wiesner, J., Weigmann, H., Härter, S., et al. (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol18: 2-9.
47.
Whitehead, C., Moss, S., Cardno, A., Lewis, G. ( 2003) Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med33: 589-599.
48.
Zink, M., Knopf, U., Mase, E., Kuwilsky, A., Deuschle, M. ( 2006) Duloxetine treatment of major depressive episodes in the course of psychotic diseases. Pharmacopsychiatry39: 109-111.
49.
Zoccali, R., Muscatello, MR, Cedro, C., Neri, P., La Torre, D., Spina, E., et al. (2004) The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol19: 71- 76.
